Clinical Trial: NCT04665856
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2026-09-18 |
Study Overview
Brief Summary
The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
Official Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Conditions
Small Cell Lung Carcinoma
Intervention / Treatment
- Drug: Tiragolumab
- Drug: Atezolizumab
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Tiragolumab Matching Placebo
Other Study ID Numbers
- YO42373
Start Date (Actual)
2020-12-21
Primary Completion Date (Actual)
2023-08-31
Study Completion Date (Actual)
2025-11-17
Enrollment (Actual)
123
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2026-09-18 |
Study Overview
Brief Summary
The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with untreated extensive-stage small cell lung cancer.
Official Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Conditions
Small Cell Lung Carcinoma
Intervention / Treatment
- Drug: Tiragolumab
- Drug: Atezolizumab
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Tiragolumab Matching Placebo
Other Study ID Numbers
- YO42373
Start Date (Actual)
2020-12-21
Primary Completion Date (Actual)
2023-08-31
Study Completion Date (Actual)
2025-11-17
Enrollment (Actual)
123
Study Type
Interventional
Phase
Phase 3